Abstract：【Objective】To systematically review the the longterm efficacy of adjuvant chemotherapy for resectable pancreatic cancer. 【Methods】Databases including MEDLINE, EBM, CBM and ASCO meeting abstracts were electronically searched for relevant randomized controlled trails (RCTs) by using the key words "pancreatic carcinoma"、"pancreatic cancer"、" pancreatic adenocarcinoma "、"adjuvant"、and "chemotherapy" in both Chinese and English. The qualities of the included studies were evaluated according to the Jadad scale and the stata 12.0 software were used for system evaluation.【Results】 A total of 9 studies were adopted, and the total number of cases was 1057. The results of a systematic review showed that survival rate after 1 year, 2 years and 3 years is higher with adjuvant chemotherapy after surgery than surgeryonly, of which adjuvant chemotherapy containing gemcitabine achieved the same benefits. For overall survival (OS), adjuvant chemotherapy after surgery is superior to surgeryonly, of which gemcitabine containing adjuvant chemotherapy also increased OS. 【Conclusion】 Compared with surgeryonly, adjuvant chemotherapy after surgery could significantly prolong survival.
2016, Vol. 33 
